[1]
Sherer, T.B.; Betarbet, R.; Greenamyre, J.T. Environment, mitochondria, and Parkinson’s disease. Neuroscientist, 2002, 8, 192-197.
[2]
Miller, R.L.; James-Kracke, M.; Sun, G.Y.; Sun, A.Y. Oxidative and inflammatory pathways in Parkinson’s disease. Neurochem. Res., 2009, 34(1), 55-65.
[3]
Colle, D.; Farina, M.; Ceccatelli, S.; Raciti, M. Paraquat and maneb exposure alters rat neural stem cell proliferation by inducing oxidative stress: New insights on pesticide-induced neurodevelopmental toxicity. Neurotox. Res., 2018, 1, 14.
[4]
Zeng, X.S.; Geng, W.S.; Jia, J.J. Neurotoxin-induced animal models of Parkinson disease: Pathogenic mechanism and assessment. ASN Neuro, 2018, 10, 175909141877743.
[5]
de Oliveira, M.R.; Peres, A.; Gama, C.S.; Dal Bosco, S.M. Pinocembrin provides mitochondrial protection by the activation of the Erk1/2-Nrf2 signaling pathway in SH-SY5Y neuroblastoma cells exposed to paraquat. Mol. Neurobiol., 2017, 54(8), 6018-6031.
[6]
Wills, J.; Credle, J.; Oaks, A.W.; Duka, V.; Lee, J.H.; Jones, J.; Sidhu, A. Paraquat, but not maneb, induces synucleinopathy and tauopathy in striata of mice through inhibition of proteasomal and autophagic pathways. PLoS One, 2012, 7(1), e30745.
[7]
Rappold, P.M.; Cui, M.; Chesser, A.S.; Tibbett, J.; Grima, J.C.; Duan, L.; Sen, N.; Javitch, J.A.; Tieu, K. Paraquat neurotoxicity is mediated by the dopamine transporter and organic cation transporter-3. Proc. Natl. Acad. Sci., 2011, 108(51), 20766-20771.
[8]
Miranda-Contreras, L.; Dávila-Ovalles, R.; Benítez-Díaz, P.; Peña-Contreras, Z.; Palacios-Prü, E. Effects of prenatal paraquat and mancozeb exposure on amino acid synaptic transmission in developing mouse cerebellar cortex. Dev. Brain Res., 2005, 160(1), 19-27.
[9]
Shiba, M.; Bower, J.H.; Maraganore, D.M.; McDonnell, S.K.; Peterson, B.J.; Ahlskog, J.E.; Schaid, D.J.; Rocca, W.A. Anxiety disorders and depressive disorders preceding Parkinson’s disease: A case-control study. Mov. Disord., 2000, 15(4), 669-677.
[10]
Chaudhuri, K.R.; Healy, D.G.; Schapira, A.H. Non-motor symptoms of Parkinson’s disease: diagnosis and management. Lancet Neurol., 2006, 5(3), 235-245.
[11]
Gilat, M.; Bell, P.T.; Martens, K.A.; Georgiades, M.J.; Hall, J.M.; Walton, C.C.; Lewis, S.J.; Shine, J.M. Dopamine depletion impairs gait automaticity by altering cortico-striatal and cerebellar processing in Parkinson’s disease. Neuroimage, 2017, 152, 207-220.
[12]
Grinberg, L.T.; Rueb, U.; di Lorenzo Alho, A.T.; Heinsen, H. Brainstem pathology and non-motor symptoms in PD. J. Neurol. Sci., 2010, 289(1-2), 81-88.
[13]
Maurice, N.; Liberge, M.; Jaouen, F.; Ztaou, S.; Hanini, M.; Camon, J.; Deisseroth, K.; Amalric, M.; Kerkerian-Le Goff, L.; Beurrier, C. Striatal cholinergic interneurons control motor behavior and basal ganglia function in experimental parkinsonism. Cell Reports, 2015, 13(4), 657-666.
[14]
Mishra, A.; Mishra, A.K.; Jha, S. Effect of traditional medicine brahmi vati and bacoside A-rich fraction of Bacopa monnieri on acute pentylenetetrazole-induced seizures, amphetamine-induced model of schizophrenia, and scopolamine-induced memory loss in laboratory animals. Epilepsy Behav., 2018, 80, 144-151.
[15]
Hosamani, R. Muralidhara. Neuroprotective efficacy of Bacopa monnieri against rotenone induced oxidative stress and neurotoxicity in Drosophila melanogaster. Neurotoxicology, 2009, 30(6), 977-985.
[16]
Zu, X.; Zhang, M.; Li, W.; Xie, H.; Lin, Z.; Yang, N.; Liu, X.; Zhang, W. Antidepressant-like effect of Bacopaside I in mice exposed to chronic unpredictable mild stress by modulating the hypothalamic-pituitary-adrenal axis function and activating BDNF signaling pathway. Neurochem. Res., 2017, 42(11), 3233-3244.
[17]
Promsuban, C.; Limsuvan, S.; Akarasereenont, P.; Tilokskulchai, K.; Tapechum, S.; Pakaprot, N. Bacopa monnieri extract enhances learning-dependent hippocampal long-term synaptic potentiation. Neuroreport, 2017, 28(16), 1031-1035.
[18]
Upadhyay, P.; Sadhu, A.; Singh, P.K.; Agrawal, A.; Ilango, K.; Purohit, S.; Dubey, G.P. Revalidation of the neuroprotective effects of a United States patented polyherbal formulation on scopolamine induced learning and memory impairment in rats. Biomed. Pharmacother., 2018, 97, 1046-1052.
[19]
Singh, B.; Pandey, S.; Yadav, S.K.; Verma, R.; Singh, S.P.; Mahdi, A.A. Role of ethanolic extract of Bacopa monnieri against 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) induced mice model via inhibition of apoptotic pathways of dopaminergic neurons. Brain Res. Bull., 2017, 135, 120-128.
[20]
Jadiya, P.; Khan, A.; Sammi, S.R.; Kaur, S.; Mir, S.S.; Nazir, A. Anti-Parkinsonian effects of Bacopa monnieri: Insights from transgenic and pharmacological Caenorhabditis elegans models of Parkinson’s disease. Biochem. Biophys. Res. Commun., 2011, 413(4), 605-610.
[21]
Singh, M.; Murthy, V.; Ramassamy, C. Neuroprotective mechanisms of the standardized extract of Bacopa monniera in a paraquat/diquat-mediated acute toxicity. Neurochem. Int., 2013, 62(5), 530-539.
[22]
Pandey, S.P.; Singh, H.K.; Prasad, S. Alterations in hippocampal oxidative stress, expression of AMPA receptor GluR2 subunit and associated spatial memory loss by Bacopa monnieri extract (CDRI-08) in streptozotocin-induced diabetes mellitus type 2 mice. PLoS One, 2015, 10(7), e0131862.
[23]
Thomas, R.B.; Joy, S.; Ajayan, M.S.; Paulose, C.S. Neuroprotective potential of Bacopa monnieri and Bacoside A against dopamine receptor dysfunction in the cerebral cortex of neonatal hypoglycaemic rats. Cell. Mol. Neurobiol., 2013, 33(8), 1065-1074.
[24]
Radi, R.; Beckman, J.S.; Bush, K.; Freeman, B.A. Peroxynitrite oxidation of sulfhydryls. The cytotoxic potential of superoxide and nitric oxide. J. Biol. Chem., 1991, 266(7), 4244-4250.
[25]
Grzelak, A.; Soszyński, M.; Bartosz, G. Inactivation of antioxidant enzymes by peroxynitrite. Scand. J. Clin. Lab. Invest., 2000, 60(4), 253-258.
[26]
Radi, R.; Cassina, A.; Hodara, R.; Quijano, C.; Castro, L. Peroxynitrite reactions and formation in mitochondria. Free Radic. Biol. Med., 2002, 33(11), 1451-1464.
[27]
Devi, L.; Ohno, M. Mitochondrial dysfunction and accumulation of the β-secretase-cleaved C-terminal fragment of APP in Alzheimer’s disease transgenic mice. Neurobiol. Dis., 2012, 45(1), 417-424.
[28]
Chen, L.; Ding, Y.; Cagniard, B.; Van Laar, A.D.; Mortimer, A.; Chi, W.; Hastings, T.G.; Kang, U.J.; Zhuang, X. Unregulated cytosolic dopamine causes neurodegeneration associated with oxidative stress in mice. J. Neurosci., 2008, 28(2), 425-433.
[29]
Rezin, G.T.; Amboni, G.; Zugno, A.I.; Quevedo, J.; Streck, E.L. Mitochondrial dysfunction and psychiatric disorders. Neurochem. Res., 2009, 34(6), 1021-1029.
[30]
Hosamani, R.; Krishna, G. Muralidhara. Standardized Bacopa monnieri extract ameliorates acute paraquat-induced oxidative stress, and neurotoxicity in prepubertal mice brain. Nutr. Neurosci., 2016, 19(10), 434-446.
[31]
Krishna, G. Muralidhara. Inulin supplementation during gestation mitigates acrylamide-induced maternal and fetal brain oxidative dysfunctions and neurotoxicity in rats. Neurotoxicol. Teratol., 2015, 49, 49-58.
[32]
Viaro, R.; Marti, M.; Morari, M. Dual motor response to L-dopa and nociceptin/ orphanin FQ receptor antagonists in 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) treated mice: Paradoxial inhibition us relieved by D2/D3 receptor blockade. Exp. Neurol., 2010, 223(2), 473-484.
[33]
Moreadith, R.W.; Fiskum, G. Isolation of mitochondria from ascites tumor cells permeabilized with digitonin. Anal. Biochem., 1984, 137(2), 360-367.
[34]
Ohkawa, H.; Ohishi, N.; Yagi, K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal. Biochem., 1979, 95(2), 351-358.
[35]
Wolff, S.P. Ferrous ion oxidation in presence of ferric ion indicator xylenol orange for measurement of hydroperoxides. Methods Enzymol., 1994, 233, 182-189.
[36]
Aebi, H. Catalase in vitro. Methods Enzymol., 1984, 105, 121-126.
[37]
Guthenberg, C.; Ålin, P.; Mannervik, B. Glutathione transferase from rat testis. Methods Enzymol., 1985, 113, 507-510.
[38]
Ellman, G.L. Courtney, K.D.; Andres Jr., V.; Featherstone, R.M. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol., 1961, 7(2), 88-95.
[39]
Dalpiaz, A.; Filosa, R.; De Caprariis, P.; Conte, G.; Bortolotti, F.; Biondi, C.; Scatturin, A.; Prasad, P.D.; Pavan, B. Molecular mechanism involved in the transport of a prodrug dopamine glycosyl conjugate. Int. J. Pharm., 2007, 336(1), 133-139.
[40]
Pennington, R.J. Biochemistry of dystrophic muscle. Mitochondrial succinate-tetrazolium reductase and adenosine triphosphatase. Biochem. J., 1961, 80(3), 649.
[41]
Berridge, M.V.; Tan, A.S. Characterization of the cellular reduction of 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT): subcellular localization, substrate dependence, and involvement of mitochondrial electron transport in MTT reduction. Arch. Biochem. Biophys., 1993, 303(2), 474-482.
[42]
Lowry, O.H.; Rosebrough, N.J.; Farr, A.L.; Randall, R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem., 1951, 193(1), 265-275.
[43]
Russo, A.; Borrelli, F. Bacopa monniera, a reputed nootropic plant: An overview. Phytomedicine, 2005, 12(4), 305-317.
[44]
Aguiar, S.; Borowski, T. Neuropharmacological review of the nootropic herb Bacopa monnieri. Rejuvenation Res., 2013, 16(4), 313-326.
[45]
Subramaniam, S.R.; Chesselet, M.F. Mitochondrial dysfunction and oxidative stress in Parkinson’s disease. Prog. Neurobiol., 2013, 106, 17-32.
[46]
Blesa, J.; Trigo-Damas, I.; Quiroga-Varela, A.; Jackson-Lewis, V.R. Oxidative stress and Parkinson’s disease. Front. Neuroanat., 2015, 9, 91.
[47]
Veal, E.A.; Day, A.M.; Morgan, B.A. Hydrogen peroxide sensing and signaling. Mol. Cell, 2007, 26(1), 1-14.
[48]
Cicchetti, F. Drouin-Ouellet.; Gross, R.E. Environmental toxins and Parkinson’s disease: What have we learned from pesticide-induced animal models? Trends Pharmacol. Sci., 2009, 30(9), 475-483.
[49]
Kaizer, R.R.; Corrêa, M.C.; Spanevello, R.M.; Morsch, V.M.; Mazzanti, C.M.; Gonçalves, J.F.; Schetinger, M.R. Acetylcholinesterase activation and enhanced lipid peroxidation after long-term exposure to low levels of aluminum on different mouse brain regions. J. Inorg. Biochem., 2005, 99(9), 1865-1870.
[50]
Le, X.T.; Pham, H.T.N.; Do, P.T.; Fujiwara, H.; Tanaka, K.; Li, F.; Van Nguyen, T.; Nguyen, K.M.; Matsumoto, K. Bacopa monnieri ameliorates memory deficits in olfactory bulbectomized mice: Possible involvement of glutamatergic and cholinergic systems. Neurochem. Res., 2013, 38(10), 2201-2215.
[51]
Chung, K.A.; Lobb, B.M.; Nutt, J.G.; Horak, F.B. Effects of a central cholinesterase inhibitor on reducing falls in Parkinson disease. Neurology, 2010, 75(14), 1263-1269.
[52]
Fiskum, G.; Starkov, A.; Polster, B.M.; Chinopoulos, C. Mitochondrial mechanisms of neural cell death and neuroprotective interventions in Parkinson’s disease. Ann. N. Y. Acad. Sci., 2003, 991(1), 111-119.
[53]
Keller, J.N.; Kindy, M.S.; Holtsberg, F.W.; Clair, D.K.S.; Yen, H.C.; Germeyer, A.; Steiner, S.M.; Bruce-Keller, A.J.; Hutchins, J.B.; Mattson, M.P. Mitochondrial manganese superoxide dismutase prevents neural apoptosis and reduces ischemic brain injury: Suppression of peroxynitrite production, lipid peroxidation, and mitochondrial dysfunction. J. Neurosci., 1998, 18(2), 687-697.
[54]
Cochemé, H.M.; Murphy, M.P. Complex I is the major site of mitochondrial superoxide production by paraquat. J. Biol. Chem., 2008, 283(4), 1786-1798.
[55]
Pawar, R.; Gopalakrishnan, C.; Bhutani, K.K. Dammarane triterpene saponin from Bacopa monniera as the superoxide inhibitor in polymorphonuclear cells. Planta Med., 2001, 67(08), 752-754.
[56]
Kowaltowski, A.J.; de Souza-Pinto, N.C.; Castilho, R.F.; Vercesi, A.E. Mitochondria and reactive oxygen species. Free Radic. Biol. Med., 2009, 47(4), 333-343.
[57]
Beal, M.F. Experimental models of Parkinson’s disease. Nat. Rev. Neurosci., 2001, 2, 325-334.
[58]
Czerniczyniec, A.; Karadayian, A.G.; Bustamante, J.; Cutrera, R.A.; Lores-Arnaiz, S. Paraquat induces behavioral changes and cortical and striatal mitochondrial dysfunction. Free Radic. Biol. Med., 2011, 51(7), 1428-1436.
[59]
Orrenius, S.; Gogvadze, V.; Zhivotovsky, B. Mitochondrial oxidative stress: Implications for cell death. Annu. Rev. Pharmacol. Toxicol., 2007, 47, 143-183.
[60]
Schrag, A. Psychiatric aspects of Parkinson’s disease. J. Neurol., 2004, 251(7), 795-804.
[61]
Santiago, R.M.; Barbieiro, J.; Lima, M.M.; Dombrowski, P.A.; Andreatini, R.; Vital, M.A. Depressive-like behaviors alterations induced by intranigral MPTP, 6-OHDA, LPS and rotenone models of Parkinson’s disease are predominantly associated with serotonin and dopamine. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2010, 34(6), 1104-1114.
[62]
Carvalho, M.M.; Campos, F.L.; Coimbra, B.; Pêgo, J.M.; Rodrigues, C.; Lima, R.; Rodrigues, A.J.; Sousa, N.; Salgado, A.J. Behavioral characterization of the 6-hydroxidopamine model of Parkinson’s disease and pharmacological rescuing of non-motor deficits. Mol. Neurodegener., 2013, 8(1), 14.
[63]
Meyer, P.M.; Strecker, K.; Kendziorra, K.; Becker, G.; Hesse, S.; Woelpl, D.; Hensel, A.; Patt, M.; Sorger, D.; Wegner, F.; Lobsien, D. Reduced α4β2*-nicotinic acetylcholine receptor binding and its relationship to mild cognitive and depressive symptoms in Parkinson disease. Arch. Gen. Psychiatry, 2009, 66(8), 866-877.
[64]
Litteljohn, D.; Mangano, E.; Shukla, N.; Hayley, S. Interferon-γ deficiency modifies the motor and co-morbid behavioral pathology and neurochemical changes provoked by the pesticide paraquat. Neuroscience, 2009, 164(4), 1894-1906.
[65]
Byler, S.L.; Boehm, G.W.; Karp, J.D.; Kohman, R.A.; Tarr, A.J.; Schallert, T.; Barth, T.M. Systemic lipopolysaccharide plus MPTP as a model of dopamine loss and gait instability in C57Bl/6J mice. Behav. Brain Res., 2009, 198(2), 434-439.
[66]
Kurz, M.J.; Pothakos, K.; Jamaluddin, S.; Scott-Pandorf, M.; Arellano, C.; Lau, Y.S. A chronic mouse model of Parkinson’s disease has a reduced gait pattern certainty. Neurosci. Lett., 2007, 429(1), 39-42.
[67]
Tinakoua, A.; Bouabid, S.; Faggiani, E.; De Deurwaerdère, P.; Lakhdar-Ghazal, N.; Benazzouz, A. The impact of combined administration of paraquat and maneb on motor and non-motor functions in the rat. Neuroscience, 2015, 311, 118-129.
[68]
Kang, M.J.; Bouabid, S.; Faggiani, E.; De Deurwaerdère, P.; Lakhdar-Ghazal, N.; Benazzouz, A. Paraquat induces alteration of the dopamine catabolic pathways and glutathione levels in the substantia nigra of mice. Toxicol. Lett., 2009, 188(2), 148-152.
[69]
Florang, V.R.; Rees, J.N.; Brogden, N.K.; Anderson, D.G.; Hurley, T.D.; Doorn, J.A. Inhibition of the oxidative metabolism of 3, 4-dihydroxyphenylacetaldehyde, a reactive intermediate of dopamine metabolism, by 4-hydroxy-2-nonenal. Neurotoxicology, 2007, 28(1), 76-82.
